LB Pharma to host in-person, virtual R&D Day spotlighting LB-102 schizophrenia program
LBRX•LB Pharmaceuticals will host an in-person and virtual R&D Day on Oct. 27, 2026, at 2:00 p.m. ET, highlighting LB-102 development ahead of a planned Phase 3 topline readout in the first half of 2027.
1. R&D Day details
LB Pharmaceuticals will host an in-person and virtual R&D Day on Oct. 27, 2026, starting at 2:00 p.m. ET. The program will spotlight development of LB-102 in schizophrenia ahead of a planned topline Phase 3 readout in the first half of 2027.
